Details

Autor(en) / Beteiligte

• Quintanilha, Mônica F.
• Miranda, Vivian C.
• Souza, Ramon O.
• Gallotti, Bruno
• Cruz, Clênio
• Santos, Elandia A.
• Alvarez-Leite, Jacqueline I.
• Jesus, Luís C.L.
• Azevedo, Vasco
• Trindade, Luísa M.
• Cardoso, Valbert N.
• Ferreira, Enio
• Carvalho, Bárbara A.
• Soares, Pedro M.G.
• Vieira, Angélica T.
• Nicoli, Jacques R.
• Martins, Flaviano S.

Titel

Bifidobacterium longum subsp. longum 51A attenuates intestinal injury against irinotecan-induced mucositis in mice

Ist Teil von

• Life sciences (1973), 2022-01, Vol.289, p.120243-120243, Article 120243

Ort / Verlag

New York: Elsevier Inc

Erscheinungsjahr

2022

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Intestinal mucositis (IM) is a critical side-effect associated with antineoplastic therapy. Treatment available is only palliative and often not effective. However, alternative therapeutic strategies, such as probiotics, have attracted significant attention due to their immune-modulatory action in several diseases. Thus, the present study aims to elucidate the therapeutic potential of the probiotic strain Bifidobacterium longum 51A in a murine model of mucositis induced by irinotecan. Due to the scarcity of studies on dose-response and viability (probiotic vs paraprobiotic), we first evaluated which dose and cell viability would be most effective in treating mucositis. In this study, the oral pretreatment with viable B. longum 51A at a concentration of 1 × 109 CFU/mL reduced the daily disease activity index (p < 0.01), protected the intestinal architecture, preserved the length of the intestine (p < 0.05), and reduced intestinal permeability (p < 0.01), inflammation, and oxidative damage (p < 0.01) induced by irinotecan. Also, treatment with B. longum 51A increased the production of secretory immunoglobulin A (p < 0.05) in the intestinal fluid of mice with mucositis. Furthermore, B. longum 51A reversed the mucositis-induced increase in Enterobacteriaceae bacterial group in the gut (p < 0.01). In conclusion, these results showed that oral administration of B. longum 51A protects mice against intestinal damage caused by irinotecan, suggesting its use as a potential probiotic in therapy during mucositis.